


**Amendments to the Claims:**

This listing of claims will replace all prior versions and listing of claims in the application.

OK TO ENTER: /PLM/ (12/07/2009)

**Listing of Claims:**

Claim 1 (previously presented): A compound of formula (I) or a salt thereof,



wherein:

**Ring A** is pyridin-2-yl wherein said pyridin-2-yl is optionally substituted on carbon by one or more groups selected from  $R^4$ ;

one of  $R^1$  and  $R^2$  is hydrogen and the other is hydrogen or  $C_{1-4}$ alkyl; wherein  $R^1$  and  $R^2$  are optionally substituted on carbon by one or more groups selected from  $R^5$ ;

$R^3$  is selected from  $C_{1-4}$ alkyl,  $C_{1-4}$ alkoxy, carbocyclyl, and carbocyclyloxy; wherein  $R^3$  is optionally substituted on carbon by one or more groups selected from  $R^6$ ;

$R^4$  is selected from halo, carboxy and  $C_{1-4}$ alkyl;

$R^5$  and  $R^6$  are independently selected from halo,  $C_{1-4}$ alkyl,  $C_{1-4}$ alkoxy,  $N$ -( $C_{1-4}$ alkyl)amino,  $N,N$ -( $C_{1-4}$ alkyl)<sub>2</sub>amino, carbocyclyl, carbocyclyloxy, and carbocyclidenyl; wherein  $R^5$  and  $R^6$  are independently optionally substituted on carbon by one or more  $R^7$ ;

$R^7$  is selected from halo, carboxy, methyl, ethyl, methoxy, ethoxy, methylamino, ethylamino, dimethylamino, diethylamino and  $N$ -methyl- $N$ -ethylamino.

Claim 2 (previously presented): The compound according to Claim 1 or a salt thereof, wherein Ring A is unsubstituted or is substituted by carboxy.

Claim 3 (previously presented): The compound according to Claim 2 or a salt thereof, wherein one of  $R^1$  and  $R^2$  is hydrogen and the other is hydrogen or  $C_{1-4}$ alkyl.

Claim 4 (previously presented): The compound according Claim 1 or a salt thereof, wherein  $R^3$  is selected from  $C_{1-4}$ alkoxy; wherein  $R^3$  is optionally substituted on carbon by one or more groups selected from  $R^6$ .

Claim 5 (currently amended): The compound according to Claim 1 or a salt thereof, wherein  $R^3$  is selected from 2-fluorobenzyloxy, 5-methylisoxazol-3-ylmethoxy and 2-thien-3-ylethoxy.

Claim 6 (currently amended): A compound according to Claim 1 selected from:

2-methyl-4-isobutoxy-6-[N-(5-carboxypyridin-2-yl)carbamoyl]benzofuran;

2-methyl-4-(2-fluorophenylmethoxy)-6-[N-(5-carboxypyridin-2-yl)carbamoyl]benzofuran; and

2-methyl-4-isobutoxy-6-[N-(5-carboxythiazol-2-yl)carbamoyl]benzofuran;

2-methyl-4-(5-methylisoxazol-3-ylmethoxy)-6-[N-(5-carboxypyridin-2-yl)carbamoyl]benzofuran;

4-(2-fluorophenylmethoxy)-6-[N-(5-carboxypyridin-2-yl)carbamoyl]benzofuran;

4-(5-methylisoxazol-3-ylmethoxy)-6-[N-(5-carboxypyridin-2-yl)carbamoyl]benzofuran;

2-methyl-4-(thien-2-ylethoxy)-6-[N-(5-carboxypyridin-2-yl)carbamoyl]benzofuran; and

2-methyl-4-isobutoxy-6-[N-(thiazol-2-yl)carbamoyl]benzofuran;

or a salt thereof.

Claim 7 (previously presented): A pharmaceutical composition comprising a compound according to any one of Claims 1 to 6, or a salt thereof, together with a pharmaceutically acceptable diluent or carrier.

Claim 8 (previously presented): A method of treating type 2 diabetes , comprising administering an effective amount of a compound according to any one of Claims 1 to 6 or a salt thereof.

Claims 9-12 (canceled)